Zefeng Xu

5.0k total citations
169 papers, 1.8k citations indexed

About

Zefeng Xu is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Zefeng Xu has authored 169 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Hematology, 65 papers in Genetics and 52 papers in Molecular Biology. Recurrent topics in Zefeng Xu's work include Acute Myeloid Leukemia Research (75 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers) and Kruppel-like factors research (20 papers). Zefeng Xu is often cited by papers focused on Acute Myeloid Leukemia Research (75 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers) and Kruppel-like factors research (20 papers). Zefeng Xu collaborates with scholars based in China, United States and United Kingdom. Zefeng Xu's co-authors include Liqiang Zheng, Zhaoqing Sun, Xingang Zhang, Dayi Hu, Tiejun Qin, Jue Li, Jiajin Li, Shuangshuang Liu, Zhijian Xiao and Robert Peter Gale and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Zefeng Xu

150 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zefeng Xu China 24 569 523 409 361 301 169 1.8k
Thomas J. Neuhaus Switzerland 30 1.4k 2.5× 427 0.8× 173 0.4× 409 1.1× 224 0.7× 107 3.5k
Dominique Guerrot France 27 576 1.0× 245 0.5× 206 0.5× 214 0.6× 93 0.3× 103 2.3k
Diego Mezzano Chile 34 461 0.8× 1.9k 3.6× 741 1.8× 388 1.1× 180 0.6× 109 3.5k
Motoshi Hattori Japan 28 544 1.0× 481 0.9× 111 0.3× 273 0.8× 146 0.5× 186 2.8k
Jaime Pereira Chile 28 291 0.5× 1.2k 2.4× 620 1.5× 222 0.6× 107 0.4× 90 2.6k
MA Siimes Finland 25 584 1.0× 342 0.7× 155 0.4× 102 0.3× 279 0.9× 46 1.8k
Johannes Jakobsen Sidelmann Denmark 21 117 0.2× 362 0.7× 249 0.6× 137 0.4× 211 0.7× 95 1.6k
Nils Egberg Sweden 29 313 0.6× 1.1k 2.2× 530 1.3× 213 0.6× 101 0.3× 119 2.5k
Yuichi Nakamura Japan 24 544 1.0× 180 0.3× 526 1.3× 154 0.4× 66 0.2× 103 1.8k
Karen Douglas United Kingdom 30 317 0.6× 505 1.0× 495 1.2× 105 0.3× 76 0.3× 69 2.7k

Countries citing papers authored by Zefeng Xu

Since Specialization
Citations

This map shows the geographic impact of Zefeng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zefeng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zefeng Xu more than expected).

Fields of papers citing papers by Zefeng Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zefeng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zefeng Xu. The network helps show where Zefeng Xu may publish in the future.

Co-authorship network of co-authors of Zefeng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Zefeng Xu. A scholar is included among the top collaborators of Zefeng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zefeng Xu. Zefeng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xie, Ying, et al.. (2025). Clinical analysis of sustained-release 5-fluorouracil implants during surgery for advanced gastric cancer. Current Problems in Surgery. 66. 101746–101746. 2 indexed citations
2.
3.
Xu, Zefeng, Jing Mi, Jing‐Feng Zhao, et al.. (2025). Magnetic Hydrogel: Enhanced Bacterial Biosensor for Speedy Gut Disease Detection. ACS Sensors. 10(11). 8424–8434.
4.
Sheng, Tian‐Lu, Jingwei Li, Xiaolong Wang, et al.. (2025). Modular brain-machine interface for neurorecording, neurostimulation, and drug delivery. Device. 3(5). 100687–100687. 1 indexed citations
5.
Liu, Jinqin, Yingying Zhao, Peihong Zhang, et al.. (2023). ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms.. PubMed. 108(5). 1359–1373. 4 indexed citations
6.
Chen, Zhenping, et al.. (2023). Clinical and molecular characteristics of forty Chinese children with essential thrombocythemia: A single‐center, retrospective analysis. British Journal of Haematology. 201(3). 520–529. 2 indexed citations
7.
8.
Zhang, Wenjun, Jinqin Liu, Lin Yang, et al.. (2023). U2AF1 S34F Mutation Promote Megakaryopoiesis and Fibrogenesis in MDS. Blood. 142(Supplement 1). 5685–5685.
9.
Geng, Guangfeng, Zefeng Xu, Nan Peng, et al.. (2021). PTBP1 is necessary for dendritic cells to regulate T‐cell homeostasis and antitumour immunity. Immunology. 163(1). 74–85. 20 indexed citations
10.
11.
Geng, Guangfeng, Jinhua Liu, Zefeng Xu, et al.. (2021). Receptor-mediated mitophagy regulates EPO production and protects against renal anemia. eLife. 10. 17 indexed citations
12.
13.
Qin, Tiejun, Zefeng Xu, Huijun Huang, et al.. (2020). [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].. PubMed Central. 41(1). 28–33. 1 indexed citations
14.
Li, Bing, Jinqin Liu, Yujiao Jia, et al.. (2017). Clinical Features and Biological Implications of U2AF1 Mutations in Myelodysplastic Syndromes. Blood. 130. 586–586. 2 indexed citations
15.
Hayashi, Yoshihiro, Rui Huang, Xiaomei Yan, et al.. (2017). HIF1A Is a Critical Downstream Mediator for Hemophagocytic Lymphohistiocytosis. Blood. 130. 3565–3565. 3 indexed citations
16.
Cui, Yajuan, Hongyan Tong, Xin Du, et al.. (2016). TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. PubMed. 3. 50–50. 9 indexed citations
17.
Cui, Yajuan, Hongyan Tong, Xin Du, et al.. (2015). Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Experimental Hematology and Oncology. 4(1). 14–14. 29 indexed citations
18.
Xu, Zefeng, Robert Peter Gale, Yue Zhang, et al.. (2012). Unique features of primary myelofibrosis in Chinese. Blood. 119(11). 2469–2473. 22 indexed citations
19.
20.
Zheng, Liqiang, Jue Li, Zhaoqing Sun, et al.. (2007). Differential Control of Systolic and Diastolic Blood Pressure: Factors Associated With Lack of Blood Pressure Control in Rural Community of Liaoning Province, China. JOURNAL OF HEALTH SCIENCE. 53(2). 209–214. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas J. Neuhaus Breakdown of academic impact, for papers by Dominique Guerrot Breakdown of academic impact, for papers by Diego Mezzano Breakdown of academic impact, for papers by Motoshi Hattori Breakdown of academic impact, for papers by Jaime Pereira Breakdown of academic impact, for papers by MA Siimes Breakdown of academic impact, for papers by Johannes Jakobsen Sidelmann Breakdown of academic impact, for papers by Nils Egberg Breakdown of academic impact, for papers by Yuichi Nakamura Breakdown of academic impact, for papers by Karen Douglas
Rankless by CCL
2026